MPO and breast cancer: Our results revealed that rosuvastatin can protect against cardiotoxicity associated with breast cancer therapy especially doxorubicin and trastuzumab documented by LVEF and proved by specific cardiac inflammatory marker, hs-cTnI and non-specific markers, MPO and IL-6.